Evidence map›Paper›PMID 25424195›Full record

ArticleOrphanet journal of rare diseases2014

TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.

John C Kingswood, Paolo Bruzzi, Paolo Curatolo, Petrus J de Vries, Carla Fladrowski, Christoph Hertzberg, Anna C Jansen, Sergiusz Jozwiak, Rima Nabbout, Matthias Sauter and 18 more

Abstract readMulticenter Study
In one paragraph

Article in Orphanet journal of rare diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. An Israeli tuberous sclerosis cohort: the efficacy of different anti-epileptic strategies.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021
    Article
  19. Article
  20. Tuberous sclerosis complex for the pulmonologist.European respiratory review : an official journal of the European Respiratory Society · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

John C KingswoodSussex Kidney Unit, Royal Sussex County Hospital, Eastern Road, Brighton, BN2 5BE, UK. chris.kingswood@bsuh.nhs.uk.
Paolo BruzziIRCCS AUO San Martino IST-Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. paolo.bruzzi@istge.it.
Paolo CuratoloTor Vergata University Hospital, Rome, Italy. curatolo@uniroma2.it.
Petrus J de VriesDivision of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa. petrus.devries@uct.ac.za.
Carla FladrowskiAssociazione Sclerosi Tuberosa ONLUS, Milan, Italy. lacarloski@gmail.com.
Christoph HertzbergVivantes-Klinikum Neukölln, Berlin, Germany. Christoph.Hertzberg@vivantes.de.
Anna C JansenUZ Brussel VUB, Brussels, Belgium. Anna.Jansen@uzbrussel.be.
Sergiusz JozwiakThe Children's Memorial Health Institute of Warsaw, Warsaw, Poland. sergiusz.jozwiak@gmail.com.
Rima NabboutHospital Necker Enfants Malades, Paris, France. rimanabbout@yahoo.com.
Matthias SauterMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany. Matthias.Sauter@med.uni-muenchen.de.
Renaud TouraineHôpital Nord, Saint Etienne, France. renaud.touraine@chu-st-etienne.fr.
Finbar O'CallaghanInstitute of Child Health, University College London, London, UK. f.o'callaghan@ucl.ac.uk.
Bernard ZonnenbergUniversity Medical Center, Utrecht, Netherlands. B.Zonnenberg@umcutrecht.nl.
Stefania CrippaNovartis Farma S.p.A., Origgio, Italy. stefania.crippa@novartis.com.
Silvia ComisNovartis Farma S.p.A., Origgio, Italy. silvia.comis@novartis.com.
Guillaume Beaure d'AugèresAssociation Sclérose Tubéreuse de Bourneville, Gradignan, France. gba.astb@gmail.com.
Elena BelousovaMoscow Institute of Pediatrics and Pediatric Surgery, Moscow, Russian Federation. ebelousova@inbox.ru.
Tom CarterTSA Tuberous Sclerosis Association, Nottingham, UK. thomase.carter@virgin.net.
Vincent CottinHôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, France. vincent.cottin@chu-lyon.fr.
Maria DahlinKarolinska University Hospital, Stockholm, Sweden. maria.dahlin@karolinska.se.
José Carlos FerreiraCentro Hospitalar Lisboa Ocidental, Lisbon, Portugal. joseccferreira@sapo.pt.
Alfons MacayaHospital Universitari Vall d'Hebron, Barcelona, Spain. amacaya@vhebron.net.
Mirjana Perkovic BenedikSPS Pediatrična Klinika, Ljubljana, Slovenia. mirjanap.benedik@gmail.com.
Valentin SanderTallinn Children Hospital, Tallinn, Estonia. valentin.sander@lastehaigla.ee.
Sotirios Youroukos"St. Sophia" Children's Hospital, Athens, Greece. sotel@hol.gr.
Ramon CastellanaNovartis Farma S.p.A., Origgio, Italy. ramon.castellana@novartis.com.
Bulent UlkerNovartis Pharma AG, Basel, Switzerland. bulent.ulker@novartis.com.
Martha FeuchtUniversitätsklinik für Kinder-und Jugendheilkunde, Vienna, Austria. martha.feucht@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberous sclerosis complex (TSC) is a rare, multisystem, genetic disorder with an estimated prevalence between 1/6800 and 1/15000. Although recent years have seen huge progress in understanding the pathophysiology and in the management of TSC, several questions remain unanswered. A disease registry could be an effective tool to gain more insights into TSC and thus help in the development of improved management strategies.

methodsTuberOus SClerosis registry to increase disease Awareness (TOSCA) is a multicentre, international disease registry to assess manifestations, interventions, and outcomes in patients with TSC. Patients of any age diagnosed with TSC, having a documented visit for TSC within the preceding 12 months, or newly diagnosed individuals are eligible. Objectives include mapping the course of TSC manifestations and their effects on prognosis, identifying patients with rare symptoms and co-morbidities, recording interventions and their outcomes, contributing to creation of an evidence-base for disease assessment and therapy, informing further research on TSC, and evaluating the quality of life of patients with TSC. The registry includes a 'core' section and subsections or 'petals'. The 'core' section is designed to record general information on patients' background collected at baseline and updated annually. Subsections will be developed over time to record additional data related to specific disease manifestations and will be updated annually. The registry aimed to enrol approximately 2000 patients from about 250 sites in 31 countries. The initial enrolment period was of 24 months. A follow-up observation period of up to 5 years is planned.

resultsA pre-planned administrative analysis of 'core' data from the first 100 patients was performed to evaluate the feasibility of the registry. Results showed a high degree of accuracy of the data collection procedure. Annual interim analyses are scheduled. Results of first interim analysis will be presented subsequent to data availability in 2014. IMPLICATIONS: The results of TOSCA will assist in filling the gaps in understanding the natural history of TSC and help in planning better management and surveillance strategies. This large-scale international registry to study TSC could serve as a model to encourage planning of similar registries for other rare diseases.

Indexed as

Disease ManagementHealth Knowledge, Attitudes, PracticeInternationalityRegistriesAwarenessCohort StudiesFemaleFollow-Up StudiesHumansMaleTuberous Sclerosis

Identifiers

PMID25424195
PMCPMC4256743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.